Personalizing androgen suppression for prostate cancer using mathematical modeling

Yoshito Hirata, Kai Morino, Koichiro Akakura, Celestia S. Higano, Kazuyuki Aihara

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Using a dataset of 150 patients treated with intermittent androgen suppression (IAS) through a fixed treatment schedule, we retrospectively designed a personalized treatment schedule mathematically for each patient. We estimated 100 sets of parameter values for each patient by randomly resampling each patient's time points to take into account the uncertainty for observations of prostate specific antigen (PSA). Then, we identified 3 types and classified patients accordingly: In type (i), the relapse, namely the divergence of PSA, can be prevented by IAS; in type (ii), the relapse can be delayed by IAS later than by continuous androgen suppression (CAS); in type (iii) IAS was not beneficial and therefore CAS would have been more appropriate in the long run. Moreover, we obtained a treatment schedule of hormone therapy by minimizing the PSA of 3 years later in the worst case scenario among the 100 parameter sets by searching exhaustively all over the possible treatment schedules. If the most frequent type among 100 sets was type (i), the maximal PSA tended to be kept less than 100 ng/ml longer in IAS than in CAS, while there was no statistical difference for the other cases. Thus, mathematically personalized IAS should be studied prospectively.

Original languageEnglish
Article number2673
JournalScientific reports
Volume8
Issue number1
DOIs
Publication statusPublished - Dec 1 2018
Externally publishedYes

Fingerprint

Androgens
Prostatic Neoplasms
Prostate-Specific Antigen
Appointments and Schedules
Therapeutics
Recurrence
Uncertainty
Hormones

All Science Journal Classification (ASJC) codes

  • General

Cite this

Personalizing androgen suppression for prostate cancer using mathematical modeling. / Hirata, Yoshito; Morino, Kai; Akakura, Koichiro; Higano, Celestia S.; Aihara, Kazuyuki.

In: Scientific reports, Vol. 8, No. 1, 2673, 01.12.2018.

Research output: Contribution to journalArticle

Hirata, Yoshito ; Morino, Kai ; Akakura, Koichiro ; Higano, Celestia S. ; Aihara, Kazuyuki. / Personalizing androgen suppression for prostate cancer using mathematical modeling. In: Scientific reports. 2018 ; Vol. 8, No. 1.
@article{5711a54ee60848ae8752f6990abf3d7b,
title = "Personalizing androgen suppression for prostate cancer using mathematical modeling",
abstract = "Using a dataset of 150 patients treated with intermittent androgen suppression (IAS) through a fixed treatment schedule, we retrospectively designed a personalized treatment schedule mathematically for each patient. We estimated 100 sets of parameter values for each patient by randomly resampling each patient's time points to take into account the uncertainty for observations of prostate specific antigen (PSA). Then, we identified 3 types and classified patients accordingly: In type (i), the relapse, namely the divergence of PSA, can be prevented by IAS; in type (ii), the relapse can be delayed by IAS later than by continuous androgen suppression (CAS); in type (iii) IAS was not beneficial and therefore CAS would have been more appropriate in the long run. Moreover, we obtained a treatment schedule of hormone therapy by minimizing the PSA of 3 years later in the worst case scenario among the 100 parameter sets by searching exhaustively all over the possible treatment schedules. If the most frequent type among 100 sets was type (i), the maximal PSA tended to be kept less than 100 ng/ml longer in IAS than in CAS, while there was no statistical difference for the other cases. Thus, mathematically personalized IAS should be studied prospectively.",
author = "Yoshito Hirata and Kai Morino and Koichiro Akakura and Higano, {Celestia S.} and Kazuyuki Aihara",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-20788-1",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Personalizing androgen suppression for prostate cancer using mathematical modeling

AU - Hirata, Yoshito

AU - Morino, Kai

AU - Akakura, Koichiro

AU - Higano, Celestia S.

AU - Aihara, Kazuyuki

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Using a dataset of 150 patients treated with intermittent androgen suppression (IAS) through a fixed treatment schedule, we retrospectively designed a personalized treatment schedule mathematically for each patient. We estimated 100 sets of parameter values for each patient by randomly resampling each patient's time points to take into account the uncertainty for observations of prostate specific antigen (PSA). Then, we identified 3 types and classified patients accordingly: In type (i), the relapse, namely the divergence of PSA, can be prevented by IAS; in type (ii), the relapse can be delayed by IAS later than by continuous androgen suppression (CAS); in type (iii) IAS was not beneficial and therefore CAS would have been more appropriate in the long run. Moreover, we obtained a treatment schedule of hormone therapy by minimizing the PSA of 3 years later in the worst case scenario among the 100 parameter sets by searching exhaustively all over the possible treatment schedules. If the most frequent type among 100 sets was type (i), the maximal PSA tended to be kept less than 100 ng/ml longer in IAS than in CAS, while there was no statistical difference for the other cases. Thus, mathematically personalized IAS should be studied prospectively.

AB - Using a dataset of 150 patients treated with intermittent androgen suppression (IAS) through a fixed treatment schedule, we retrospectively designed a personalized treatment schedule mathematically for each patient. We estimated 100 sets of parameter values for each patient by randomly resampling each patient's time points to take into account the uncertainty for observations of prostate specific antigen (PSA). Then, we identified 3 types and classified patients accordingly: In type (i), the relapse, namely the divergence of PSA, can be prevented by IAS; in type (ii), the relapse can be delayed by IAS later than by continuous androgen suppression (CAS); in type (iii) IAS was not beneficial and therefore CAS would have been more appropriate in the long run. Moreover, we obtained a treatment schedule of hormone therapy by minimizing the PSA of 3 years later in the worst case scenario among the 100 parameter sets by searching exhaustively all over the possible treatment schedules. If the most frequent type among 100 sets was type (i), the maximal PSA tended to be kept less than 100 ng/ml longer in IAS than in CAS, while there was no statistical difference for the other cases. Thus, mathematically personalized IAS should be studied prospectively.

UR - http://www.scopus.com/inward/record.url?scp=85041900276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041900276&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-20788-1

DO - 10.1038/s41598-018-20788-1

M3 - Article

C2 - 29422657

AN - SCOPUS:85041900276

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 2673

ER -